Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients. a
preliminary validation of the opioid risk tool. Pain Medicine 2005; 6: 432-442.
Weiner DK, Distell B, Studenski S, Martinez S, Lomasney L, Bongiorni D. Does radio-
graphic osteoarthritis correlate with flexibility of the lumbar spine? Journal of the
American Geriatric Society 1994; 42: 257-263.
Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakt-
hrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-
label safety study. Cancer 2009; 115(11): 2571-2579.
Wertheim M, Jhangiani H, Niebler G, Charu V. Finding an effective dose of fentanyl
effervescent buccal tablets: combined results of open-label titration. J Clin Oncol 2006;
Wheeler M, Birmingham PK, Dsida RM, Wang Z, Coté CJ, Avram MJ. Uptake pharmaco-
kinetics of the fentanyl oralet in children scheduled for central venous access removal:
implications for the timing of initiating painful procedures. Paediatr Anaesth 2002;
Wild MR, Espie CA. The efficacy of hypnosis in the reduction of procedural pain and
distress in pediatric oncology. A systematic review. Journal of Developmental and Beha-
vioral Pediatrics 2004; 25: 207-213.
Wong G. Effect of neurolytic celiac plexus block on pain relief, quality of life, and sur-
vival in patients with unresectable pancreatic cancer. Journal of the American Medical
Association 2004; 291: 1092-1099.
Younge PA, Nicole MF, Kendall JM. A prospective randomised pilot comparison of intra-
nasal fentanyl and intramuscular morphine for analgesia in children presenting to the
emergency department with clinical fractures. Emerg Med 1999; 11: 90-94.
Zarth R, Ehmer M, Sittig HB. Oral transmucosal fentanyl citrate for the treatment of
breakthrough pain. Results of a non-interventional study (NIS). Schmerz 2007; 21(6):
Zeppetella G, Messina J, Xie F, Slatkin NE. Consistent and clinically relevant effects with
fentanyl buccal tablet in the treatment of patients receiving maintenance opioid thera-
py and experiencing cancer-related breakthrough pain. Pain Pract 2010; 10(4): 287-293.
Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough
pain in cancer patients admitted to a hospice [published erratum appears in J Pain
Symptom Manage 2001; 21(3): 265].
Zeppetella G, Ribeiro MD. Episodic pain in patients with advanced cancer. American
Journal of Hospice and Palliative Care 2002; 19: 267-276.
Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain
in cancer patients. Cochrane Database Syst Rev 2006; (1): CD004311.
Zeppetella G, Ribeiro MD. Pharmacotherapy of cancer-related episodic pain. Expert
Opinion on Pharmacotherapy 2003; 4(4): 493-502.
Zeppetella G. Breakthrough pain should be distinguished from background pain. Guide-
lines in Practice 2009; 12(3): 1-5.